BioStem Technologies Schedules First Quarter 2026 Financial Results Conference Call

BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced today that it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide a business update.

Management will review the quarter’s financial performance, operational highlights, and strategic initiatives during the webcast. Interested parties can register for the event through the provided webcast link. The conference call can be accessed via North America toll-free at (800) 715-9871 or internationally at +1 (646) 307-1963, using conference ID 9695874.

BioStem Technologies focuses on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company utilizes proprietary processing technologies, including BioRetain®, CryoTek®, and SteriTek®, to preserve the natural properties of these tissues for clinical use. Its product portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™, serving clinicians across various specialties.

The company’s quality management systems are accredited by the American Association of Tissue Banks (AATB) and comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). BioStem continues to expand its clinical research initiatives and national commercial footprint, aiming to advance innovation in regenerative medicine.

For more information and updates on BioStem Technologies, visit the company’s newsroom at https://tinyurl.com/bsemnewsroom.